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KEY POINTS
 Extensively drug resistant and pan–drug-resistant gram-negatives represent a global pub-
lic health challenge Q10.
 Rapid commercial phenotypic antimicrobial susceptibility tests now are available for lab-
oratory use.
 Detection of resistance genes can be rapidly accomplished in cultures by immunoassays
and nucleic acid amplification testing–based methods.
 Whole-genome sequencing directly on specimens is being developed for clinical
applications.
 Advances have been made with direct detection of resistance genes from specimens.INTRODUCTION
The clinical microbiology laboratory is challenged with detecting and characterizing
antimicrobial resistance (AMR) in gram-negatives. Examples of recent and emerging
resistance include the detection of extensively/pan–drug-resistant Enterobacterales,
Pseudomonas aeruginosa, and Acinetobacter spp producing carbapenemases (eg,
KPC, NDM, and OXA types) together with other traits, such as 16S rRNA methylases
and MCR, conferring resistance to aminoglycosides and polymyxins, respectively.1–3a Institute for Infectious Diseases, Faculty of Medicine, University of Bern, Bern, Switzerland;
b Department of Pathology, Case Western Reserve University and University Hospitals Cleve-
land Medical Center, Cleveland, OH, USA
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99More rapid identification of AMR is a perpetual goal. Increased emphasis on rapid
detection of resistance has focused on infections with the highest morbidity and mor-
tality, in particular sepsis associated with bloodstream infections (BSIs). A mean
decrease in survival of 7.6% for each hour after onset of infection until effective anti-
biotics are administered has been reported in sepsis.4 Recent studies also have docu-
mented the value of more rapid resistance detection by the laboratory, which needs to
be paired with more extralaboratory intervention. Rapid resistance detection has been
shown to improve patient outcomes, with lower mortality, decreased hospital length of
stay, lower superinfection and adverse drug reaction rates, and decreased costs.5
Although the rapid detection of bacteria and their resistance mechanisms directly
from blood specimens is still a challenging target, this has been achieved on growing
blood cultures (BCs), which typically become positive after 12 hours to 16 hours of in-
cubation.6 Many systems for rapid bacterial identification from positive BCs have been
developed and, more recently, rapid automated antimicrobial susceptibility tests
(ASTs) have been made available. Many of these systems also can detect AMR genes
(ARGs).Q15
Q16
Q17AVAILABLE METHODS
Standard Antimicrobial Susceptibility Test Methods
Conventional AST procedures have been in use for many decades and followmethods
and interpretations of various organizations, such as European Committee on Antimi-
crobial Susceptibility Testing and Clinical and Laboratory Standards Institute (CLSI)7,8
as well as regulatory agencies such as US Food and Drug Administration (FDA) and
European Agency for the Evaluation of Medicinal Products. These organizations
have established reference AST methods based on minimum inhibitory concentration
determination by microdilution and agar dilution, with incubation times ranging from
18 hours to 48 hours. Disk diffusion methods also have been standardized.
Many commercial methods for AST are available and are based on using these
methods directly or by methods providing comparable results. Commercial systems
using reference microdilution methods include, for instance, MicroScan WalkAway
(Beckman) and Sensititre (Thermo Fisher Scientific). Methods providing results com-
parable to reference testing include gradient diffusion minimum inhibitory concentra-
tion determination (Etest [bioMérieux] and MTS [Liofilchem]), and automated
systems, such as Vitek (bioMérieux), Phoenix (BD Diagnostic Systems), and the
rapid versions of MicroScan and Sensititre. Several of the methods have faster turn-
around time (TAT) than reference methods, and those automated are coupled with
machine-generated results. Instruments that record and interpret disk diffusion
zone also are available (eg, ADAGIO [Bio-Rad]; Scan 1200 [Interscience]; and SIR-
scan [i2a]). Faster TAT also is available for disk diffusion testing using standard
and enhanced media.9,10
Antimicrobial Susceptibility Test Methods to Detect Resistance Mechanisms
These reference AST methods include methods for determination of resistance mech-
anisms, such as (1) the presence of extended spectrum b-lactamases (ESBLs) using
cefotaxime and ceftazidime alone and combined with clavulanate and (2) the presence
of carbapenemases using lowered carbapenem breakpoints, the modified carbape-
nem inactivation method, and enzyme inhibitors (eg, boronic and dipicolinic acids).7,11
These approaches are incorporated in many commercially available systems, such as
those automated (eg, the Phoenix system)12 or those based on disk diffusion (eg, the
disk diffusion Neo-Rapid CARB kit [Rosco]).13IDC1037_proof ■ 12 September 2020 ■ 4:45 pm
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The rapid AST systems include those based on flow cytometry; microfluidic; real-time
high-resolution video imager; ATP bioluminescence; cell lysis; nanoechanical, electro-
echanical, and optomechanical; and other techniques (reviewed by Endimiani and Ja-
cobs14 and by Behera and colleagues15). Only several, so far, however, are available
commercially.
The Accelerate Pheno system (Accelerate Diagnostics) combines species identifi-
cation (ID) through fluorescence in situ hybridization probes with rapid ASTs based
on time-lapse automated morphokinetic cell microscopic analysis. Both ID and AST
are performed automatically on positive BCs, with results provided in maximum 1.5
hours and 7 hours, respectively (at least 24 hours before those provided with routine
approaches).16 In a recent study, the system accurately identified the pathogens with
a sensitivity ranging from 94.6% to 100%, whereas for the AST results, the categorical
agreement was 97.9%.17 Overall, the Accelerate Pheno system may significantly
anticipate the definitive antibiotic therapy, improving the outcome of BSI patients.18
The Alfred 60 (Alifax) is another automatic AST system implemented for positive
BCs that provides results in approximately 6 hours. It analyzes the turbidity of bacteria
that grow in broth and has demonstrated a 93% categorical agreement with the stan-
dard ASTs.19Q20
Q21Rapid Biochemical Tests to Detect Extended Spectrum b-Lactamase and
Carbapenemase Producers
The ESBL NDP test is a rapid (15 minutes to 2 hours) and cost-effective biochemical
test used to detect ESBL producers. ESBL production is evidenced by a color change
(red to yellow) of the pH indicator phenol red due to acid formation resulting from
cefotaxime hydrolysis that is reversed by adding tazobactam, with reported 93%
sensitivity and 100% specificity for detecting ESBL-producing Enterobacterales
(ESBL-PE). The test has been evaluated on BC and urine samples, showing excellent
sensitivity and specificity (>98% and >99%, respectively). This homemade test has
been upgraded to a commercially available kit named Rapid ESBL NP test.20
The Carba NP test is an in-house assay designed to detect carbapenemase pro-
ducers. It detects a change in pH due to the hydrolysis of imipenem in presence of car-
bapenemases in less than 2 hours. b-Lactamases are extracted rapidly from bacterial
cells and then incubated with imipenem and phenol red. This test demonstrated an
excellent ability to detect carbapenemases in Enterobacterales and Pseudomonas
spp, as well as in Acinetobacter spp, in an improved version (CarbAcineto NP
test),20,21 although there are concerns regarding the low sensitivity for OXA-48–like
producers. The test also was implemented directly on positive BCs with
carbapenemase-producing Enterobacterales (CPE) and Pseudomonas spp, demon-
strating greater than 98% sensitivity and 100% specificity.22,23 Notably, the Carba
NP test is recommended for the confirmation of carbapenemase production in
gram-negatives by the CLSI.7 This test now is available commercially in an easy-to-
use rapid kit (RAPIDEC Carba NP test [bioMérieux]). Another version of the original
Carba NP test (Carba NP II test) includes additional wells with clavulanic acid and
EDTA, making the assay able to distinguish the different classes of carbapene-
mases.24 This test, however, is not commercially available.20
The Blue-Carba test is another in-house biochemical assay for carbapenemases
detection, but it uses a different indicator (bromothymol blue) and a simplified protocol
compared with the Carba NP test. The main advantage of the Blue-Carba is its faster
TAT, because there is no need to extract the b-lactamase(s) from colonies. Overall, theIDC1037_proof ■ 12 September 2020 ■ 4:45 pm
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201test shows comparable performance to the in-house Carba NP, with reported better
sensitivity for the detection of OXA-type carbapenemases.25 In a recent study with
CPE, Carba NP had higher specificity than Blue-Carba (98.9% vs 91.7%, respec-
tively), whereas both tests had 100% sensitivity.26 A commercially available version
of Carba NP (Neo-CARB kit, formerly Rapid CARB Screen ) has shown similar sensi-
tivity (97% vs 98%, respectively) but superior specificity (100% vs 83%) compared
with the Carba NP test.27 In contrast, in another evaluation, the Carba NP had sensi-
tivities of 91% for Enterobacterales and 100% for P aeruginosa, whereas those for the
Rapid CARB Screen kit were 73% and 67%, respectively; the specificity of both tests
was 100%.28
b LACTA and b CARBA tests (Bio-Rad) are commercially available tests used for the
detection of ESBL-PE and CPE, respectively. They rely on the use of chromogenic
b-lactams that yield a different color when they are hydrolyzed by the b-lactamase
(from yellow to red). Both tests are easy to perform and the results are obtained within
1 hour.29 The b LACTA test has been evaluated not only with colonies but also directly
from blood, urine, and bronchial samples. These samples yielded both specificity and
sensitivity of 100%.30 The b CARBA test showed high sensitivity (98%) and specificity
(100%) in detecting CPE, including those producing OXA-48–like enzymes, from cul-
tures.31 Recently, it has been used directly on the pellet of positive spiked BCs: all CPE
were detected and no false-positive results were recorded. Sensitivity and specificity
were 100% and 94%, respectively, with TATs ranging between 20 minutes and
45 minutes.32
Biochemical Tests to Detect Other Resistance Phenotypes
The Rapid Polymyxin NP test (ELITechGroup) is a commercial assay that quickly de-
tects polymyxin resistance quickly. This test is based on the detection of glucose
metabolism related to bacterial growth (when resistant to polymyxins) in the presence
of a defined concentration of colistin. The formation of acid metabolites is evidenced
by a color change of the pH indicator red phenol in less than 2 hours. The assay
showed greater than 98% sensitivity and greater than 94% specificity.33,34 It also
was evaluated for detection of colistin-resistant Enterobacterales directly from BCs,
exhibiting excellent discrimination between colistin resistant and susceptible
isolates.35
Based on the same principle used in the Rapid Polymyxin NP, further rapid pheno-
typic tests to detect aminoglycoside-resistant and fosfomycin-resistant Enterobacter-
ales have been developed.36,37 Because Acinetobacter baumannii and P aeruginosa
do not metabolize glucose, a new assay (Rapid ResaPolymyxin Acinetobacter/Pseu-
domonas NP test) based on the utilization of resazurin (alamarBlue) has been devel-
oped. Metabolically active cells (polymyxin-resistant) reduce blue resazurin to the
pink product resorufin. In less than 4 hours, the test showed 100% sensitivity and
95% specificity.38
Immunochromatographic Tests
Antigen detection can be used to detect enzymes or cell components of bacteria that
are associated with AMR. The immunochromatographic tests often are lateral flow as-
says (LFAs) where antigen detection is identified by visualization of a line (as in preg-
nancy tests). These LFAs are useful because of their rapidity (results within
15 minutes), low cost, and accuracy that typically are comparable to nucleic acid
amplification testing.39
The LFAs designed to detect b-lactamases started being commercialized in 2015 to
2016. Although at the beginning they were targeting only one enzyme (eg, OXA-48),40IDC1037_proof ■ 12 September 2020 ■ 4:45 pm
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BioConcept) detects OXA-48–like, KPC, NDM, and VIM carbapenemases, with
greater than 99% sensitivity and 100% specificity in culture strains belonging to Enter-
obacterales and Pseudomonas spp.41 The NG-Test CARBA 5 (NG Biotech) detects
the 5 most common carbapenemases: KPC, OXA-48–like, VIM, IMP, and NDM. Hav-
ing shown 99.3% sensitivity and 99.8% specificity for cultured colonies,42 this LFA
now is FDA-cleared. Remarkably, CARBA 5 also has demonstrated high accuracy
when testing positive BCs for detecting CPE (sensitivity and specificity of >97.7%
and >96.1%, respectively).43,44 An LFA to detect the colistin resistance traits MCR-
1 also has been developed.45
Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectroscopy
Thematrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spec-
troscopy (MS) nowadays is used routinely to identify bacterial species from growth on
agar plates as well as organisms present in positive BCs. Overall, the main advantages
of MALDI-TOF MS are its speed, relatively low costs, and consistency.46
Numerous studies also have assessed the utility of MALDI-TOF MS for the identifi-
cation of b-lactam degradation products in the presence of hydrolyzing b-lactamases,
including directly from positive BCs and urine. In particular, many investigators have
evaluated the identification of carbapenemase producers where antibiotics (imipe-
nem, meropenem, and ertapenem) are incubated with the organism and then analyzed
for degradation products of the antibiotics with the MS; the time required to do this
assay is approximately 1 hour to 4 hours.47 Bruker Daltonics also produces the
MBT STAR-Carba IVD commercial kit to rapidly detect carbapenemase producers.
The assay showed high sensitivity (100%) and specificity (>98%) for CPE but not
for OXA-23/-24–producing A baumannii.48,49 All of these MALDI-TOF MS approaches,
however, can detect only the presence of b-lactam hydrolysis as a generic resistance
mechanism and not the specific enzyme (eg, distinguishing NDM from KPC); this iden-
tical information can be obtained easily by implementing rapid and cost-effective
biochemical tests (discussed previously) or polymerase chain reaction (PCR)-based
methods. The MALDI-TOF MS is able to detect the specific KPC-2 peak (280544 m/
z) in Enterobacterales and P aeruginosawith both sensitivity and specificity of 100%.50
Single and Multiplex Endpoint Polymerase Chain Reaction
A single PCR frequently is sufficient for detection of a unique ARG of interest. Subse-
quent DNA sequencing, however, may be necessary (eg, to distinguish SHVs with
ESBL from those with non-ESBL spectrum). Results of PCR amplification can be ob-
tained in less than 3 hours to 4 hours for simple amplification to greater than or equal to
24 hours if DNA sequencing is required. Making use of multiple primer sets, multiplex
endpoint PCRs have the advantage of simultaneously amplifying many different tar-
gets. In the past, numerous single and multiplex PCRs have been designed to detect
ARGs, including ESBL, carbapenemase, aminoglycoside-modifying enzyme, and
outer membrane porin genes associated with carbapenem resistance (revised by
Endimiani and Jacobs14 and Lupo and colleagues51).
Single and Multiplex Real-Time Polymerase Chain Reaction
Real-time PCR consists of an amplification reaction of the target gene coupled with
the detection of the exponentially amplified DNA product by various methods, such
as monitoring fluorescence emission with SYBR Green or TaqMan probes. Real-
time PCR avoids time consuming steps, such as running gels; is sensitive, reliable,
and cost-effective; and usually does not require DNA sequencing. ModernIDC1037_proof ■ 12 September 2020 ■ 4:45 pm
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303apparatuses also can perform a high-resolution melting analysis of DNA products, giv-
ing information on single-nucleotide polymorphisms in the sequence.52
Many in-house single or multiplex platforms for detecting plasmid-mediated AmpC
(pAmpC), ESBL, carbapenemase, and other ARGs have been designed (eg, Endimiani
and Jacobs14 and Lupo and colleagues51), and many commercially available kits now
are available. For example, Check-Points Health B.V. provides quantitative multiplex
real-time PCR kits to detect ESBL and carbapenemase genes directly from peri/rectal
swabs. Results are available within 2 hours to 3 hours, along with genotypic differen-
tiation of the bla types based on probes labeled with different fluorescent dyes. Kits
can be adapted to the BD MAX system (Becton-Dickinson), a diagnostic platform
that operates as an open real-time PCR, allowing automated sample lysis, extraction,
amplification, and detection processes. The Check-Direct ESBL screening kit detects
CTX-M and SHV ESBL genes. For rectal swabs, it displayed sensitivity of 88% to 95%
and specificity of 96% to 99%.53,54 The Check-Direct CPE assay identifies blaKPC,
blaNDM, blaVIM, and blaOXA-48-like, with reported sensitivity of 100% and specificity of
88% to 100%, respectively. Moreover, compared with standard approaches, this mo-
lecular system reduced TAT from 18 hours to 24 hours (using direct culture) or 48 hours
(using broth enrichment) to only 3 hours.55–58 For both Check-Direct kits, false-
positive results (negative by culture) can arise from the presence of DNA residual of
dead bacteria, or detection of bacteria harboring, but not expressing, bla
genes.53,54,56,58
GeneXpert (Cepheid) is another real-time PCR system that performs fully automated
nucleic acid detection and analysis directly from clinical samples. To minimize
contamination, it is a cartridge-based, closed, self-contained platform. The company
provides many cartridges for detection of different pathogens and ARGs. Among
them, the Xpert Carba-R (v2) cartridge is designed to detect blaKPC, blaNDM, blaIMP,
blaVIM, and blaOXA-48-like, requiring 2 minutes of hands-on time and less than 48 minute
to achieve results.59 For rectal swabs, this kit demonstrated overall sensitivity of 97%
to 100% and specificity of 99%. As for Check-Direct, the Xpert Carba-R assay re-
ported the presence of carbapenemase genes in culture-negative samples.60,61 In
another study, Xpert Carba-R was implemented for rapid screening for colonization
with carbapenemase-producing species, coupled with implementation of infection
prevention strategies. Isolation of positive patients led to a reduction in both coloniza-
tion (from 28.6% to 5.6%; P<.05) and infection (from 35.7% to 2.8%; P<.05) rates dur-
ing the study period.62
Other companies have developed further real-time PCR-based platforms to detect
carbapenemases, mcr-1/-2 associated with polymyxins resistance and other ARGs.
Examples include PANA RealTyper CRE kit (PANAGENE)63; Tandem-Plex CRE EU
kit (AusDiagnostics)64; Acuitas AMR Gene Panel (OpGen)65; and GenePOC Carba/
Revogene Carba C assay (Meridian Bioscience).66 Their analytical performance
directly on clinical samples, however, has not yet been extensively evaluated.
BioFire FilmArray
The BioFire FilmArray (bioMérieux) is a closed, very rapid (1-hour), fully automated
system (only 2 minutes hands-on-time) that combines DNA extraction from samples,
nested multiplex PCRs, post-PCR amplicon high-resolution melting analysis, and
automated interpretation of results.67 This method initially was developed for the
detection of respiratory pathogens,68 but later additional assays have been devel-
oped. The FilmArray Blood Culture Identification (BCID) kit has been approved by
FDA for direct implementation on positive BCs. It identifies 27 targets, including
gram-positives, gram-negatives, 6 Candida spp, and the ARGs mecA, vanA/B, andIDC1037_proof ■ 12 September 2020 ■ 4:45 pm
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354blaKPC. Similarly, the FilmArray Pneumonia Panel plus has 34 targets, including 27 ma-
jor respiratory pathogens and several ARGs (mecA/C, blaKPC, blaNDM, blaVIM, blaIMP,
blaOXA-48-like, blaCTX-M, and blaKPC).
The FilmArray BCID has been evaluated in numerous recent studies. In a large multi-
center trial (2207 samples), the system showed an identification sensitivity greater
than 96%. Moreover, sensitivity and specificity for mecA were both 98%, whereas
those for vanA/B and blaKPC were both 100%.
69 In another study, it was shown that
the use of the BCID system reduced the time to optimal antimicrobial treatment in
ICU patients by an average of 10 hours (from 15 hours to 5 hours; P<.05).70 Although
focusing on bacteremia due to gram-positives, another analysis showed that the
implementation of the BCID panel resulted in shorter postculture length of stay and
saved approximately $30,000 per 100 patients tested.71 A new BC panel (BCID2),
able to detect further species and ARGs (including major carbapenemases and
mcr-1), will be released shortly.
Loop-Mediated Isothermal Amplification
The loop-mediated isothermal amplification (LAMP) method allows amplification and
fluorescent detection of the target DNA at a constant temperature, avoiding the
need for a thermocycler. Genomic extraction from samples is not required as the ac-
tivity of the Bst DNA polymerase is not hampered by serum or heparin.72 Recently,
many investigators have designed in-house LAMP platforms to detect different
ARGs. Overall, for clinical samples the LAMPwas very rapid (<1-hour), more sensitive,
and with a lower limit of detection than PCR-based approaches.14,73,74
The commercially available eazyplex LAMP system (Amplex Diagnostics) consists
of a series of freeze-dried and ready-to-use kits coupled by real-time photometric
detection of amplified targets using the transportable Genie II instrument (OptiGene).
One of the kits was designed to detect KPC, NDM, OXA-48, VIM, OXA-23, OXA-24/40,
and OXA-58 carbapenemase genes. Its first evaluation was performed on Acineto-
bacter spp and all isolates were characterized correctly in less than 30 minutes.75 In
another study focusing on Enterobacterales, an advanced kit (eazyplex SuperBug
CRE kit) was assessed to detect KPC, VIM, NDM, OXA-48–like, and CTX-M-1/-9–
like genes: all carbapenemase and/or CTX-M producers were identified correctly
within 15 minutes.76
The same kit also was used directly on 50 urine samples, 30 of which contained
ESBL producers; the assay showed sensitivity of 100% and specificity of 97.9%,
with results obtained in less than 20 minutes.77 Recently, it was shown that implemen-
tation of the eazyplex SuperBug CRE kit on positive BCs significantly improved the
clinical outcome of BSIs due to CTX-M- and/or KPC/VIM-producing Escherichia coli
and Klebsiella pneumoniae. In particular, after notification of SuperBug CRE results
(on average 20 hours after sample collection), the proportion of appropriate treatment
increased from 6% to 71% and from 30% to 92% for BSIs caused by KPC/VIM and
CTX-M producers, respectively.78 Extended kit versions able to further detect
pAmpCs (eazyplex AmpC), OXA-23–like, OXA-24/40–like, OXA-58–like, and OXA-
181–like (eazyplex SuperBug complete A/B/C and Acineto), IMI, GES, GIM (eazyplex
SuperBug expert), and themcr-1 (eazyplex SuperBug mcr-1) genes also are available.
Microarrays
Microarrays possess great diagnostic capacity because they can simultaneously
detect and analyze a large number of target genes.79 In the past, numerous in-
house assays have been designed to characterize ARGs, but their implementation
was difficult because of problems related to standardization of the procedures.IDC1037_proof ■ 12 September 2020 ■ 4:45 pm
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forms are easy to perform and can be updated readily, although the TAT is rather
long (6–8 hours) and commercial kits are relatively expensive.51
Check-Points Health B.V. has developed an automated DNA microarray platform to
detect the major bla genes. Over the past 10 years, several kits have been released,
including Check KPC/ESBL, Check-MDR CT101, CT102, CT103, and CT103XL. Over-
all, these assays showed high accuracy in detecting ESBL, pAmpC, and carbapenem-
ase genes in cultured strains.80–82 Moreover, one of these kits (Check-KPC/ESBL) was
used to detect ESBL and KPC genes directly from positive BCs, reducing the reporting
time of these resistance traits by 18 hours to 20 hours.83 The latest microarray kit
made available by the company (New Check-MDR CT103XL) can detect the most
epidemiologically important ESBL, pAmpC, and carbapenemase, along with the
mcr-1 and mcr-2 genes. In a recent evaluation against a collection of Enterobacter-
ales, all bla and mcr-1/2 genes were correctly identified.84
Verigene System
Verigene (Luminex Corporation) is an automated multiplex microarray-based system
that uses small aliquots of positive BC broths to identify a panel of major bacterial
pathogens and ARGs. Results are available within 2.5 hours from Gram stain result
on positive BCs. The test uses a disposable kit and cartridge, the latter inserted in a
processor (5-minute hands-on-time) that carries out extraction of nucleic acid and
microarray reactions. Final results are obtained by inserting the cartridge into a dedi-
cated reader. Assays for gram-positives and gram-negatives are available. The Veri-
gene gram-negative BC nucleic acid (BC-GN) test can identify E coli, K
pneumoniae, K oxytoca, P aeruginosa, S marcescens, Acinetobacter spp, Proteus
spp, Citrobacter spp, Enterobacter spp, and the ARGs blaKPC, blaNDM, blaCTX-M, bla-
VIM, blaIMP, and blaOXA. In a large study (1847 BCs), agreement of the BC-GN assay with
the reference method for monomicrobial cultures was E coli, 100%; K pneumoniae,
92.9%; P aeruginosa, 98.9%; and Acinetobacter spp, 98.4%. Agreement for identifi-
cation of ARGs was blaCTX-M, 98.9%; blaKPC/VIM/IMP, 100%; blaNDM, 96.2%; and
blaOXA, 94.3%.
85
Numerous studies also have demonstrated that implementation of Verigene BC-GN
has a significant positive clinical impact. For instance, it was shown that ID (mean
10.9 hours vs 37.9 hours, respectively; P<.001) and time to effective therapy for BSI
due to ESBL producers were achieved more quickly (mean 7.3 hours vs 41.4 hours,
respectively; P 5 .04); moreover, length of intensive care unit (ICU) stay (12.0 days
vs 16.2 days, respectively) and 30-day mortality (8.1% vs 19.2%, respectively) were
significantly lowered.86
T2 Magnetic Resonance
The T2 magnetic resonance (T2MR) (T2 Biosystems) is a recently marketed system
that combines PCR amplification, hybridization with nanoparticles and T2MR in a
closed apparatus to detect diverse targets directly from complex matrices, such as
blood.87 With a limit of detection of 1 colony-forming unit/mL, the system can identify
5 Candida spp (T2Candida Panel) or E faecium, Staphylococcus aureus, K pneumo-
niae, P aeruginosa, and E coli (T2Bacteria Panel) from 2 mL of whole blood.88 In
ICU patients, T2Bacteria Panel showed sensitivity of 83.3% and specificity of
97.6% in detecting bacterial targets that were present in BCs. Sensitivity increased
to 89.5% when patients with clinical indication of infection, regardless of BC results,
were considered. A considerable number of patients, especially those receiving anti-
microbials, had T2Bacteria-positive/BC-negative results. Mean times to detection ofIDC1037_proof ■ 12 September 2020 ■ 4:45 pm
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456species or negative results were 5.5 hours and 6.1 hours, respectively; in comparison,
those for conventional BCs were 25.2 hours and 120 hours, respectively.89 Recently,
the company has developed a panel (T2Resistance) to rapidly detect 13 ARGs (blaKPC,
blaNDM/IMP/VIM, blaOXA-48, blaCTX-M-14/15, blaCMY/DHA, vanA/B, and mecA/C).
Next-Generation Sequencing
In the clinical setting, whole-genome sequencing of bacteria increasingly is used to
inform on the emergence and spread of AMR, with the final objective to better tailor
antimicrobial prescription.90,91 No method other than pathogen genomic sequencing
can deliver complete ARG and species identification directly from positive BCs or pro-
vide a full picture of the susceptibility profile as well as insights about novelty, trans-
mission, and virulence of associated genetic elements. Genomic workflows typically
involve several steps, from raw sequence data production to the further processing
of the generated data into interpretable nucleic acid sequences using bioinformatic
tools.
Over the past 15 years, the low-throughput, costly, yet accurate, Sanger
sequencing has been replaced by high-throughput sequencing technologies, such
as 454 pyrosequencing (discontinued in 2013) and Illumina sequencing. Currently,
clinical genomic applications are based mostly on Illumina sequencing technology,
which allows for the sequencing of entire genomes in mixed samples or the detection
of sequence variants with enough coverage and with satisfactory base accuracy.92
Although successfully used to profile human-associated antibiotic resistomes (eg,
Forsberg and colleagues93 and Gonzalez-Escalona and collaegues94), the short reads
(few hundreds of bases) produced by the Illumina technology may lead to downstream
sequence processing difficulties (eg, for contig assembly), especially when multiple
copies of the same genes, high GC, or homopolymeric regions are present in the
target genome.95
High-quality de novomicrobial genome assemblies can alternatively be obtained via
Pacific Biosciences SMRT sequencing, which may produce sequences efficiently,
even when long repeat regions are present.96 The via Pacific Biosciences technology
introduced in 2011, however, needs significant capital investment, dedicated
personnel, and laboratory space, which may explain why only few applications have
been reported in the clinical setting.92 Consequently, clinically applicable workflows
that provide straightforward, affordable, and comprehensive resistome characteriza-
tion still are lacking, and technologies addressing those needs are highly desirable.
Oxford Nanopore Technologies introduced its first product, MinION, consisting of a
single-molecule sensing system embedded in a cheap, light-weight (100-g)
sequencer.97 Nanopore sequencing works by threading individual DNA or RNA mole-
cules through nanoscopic pores fixed to a membrane on which an ionic current is
applied. As the molecule passes through the pore, the current is altered as a function
of the identity of the base and of its residues. This signal then is recorded and con-
verted into a nucleotide sequence by a suite of bioinformatic tools, while further pro-
cessing of the data is done using software scripts provided by the company and by the
user community. The strategy of Oxford Nanopore Technologies was to let a limited
number of laboratories assess the sequencing performance of the device, acknowl-
edging the developing nature of the technology. This early access to this technology
has helped rapidly develop wet laboratory protocols, software scripts to optimize the
sequencing process and also downstream analyses by a large group of users. It also
lets users explore potential applications, thus contributing to publicize the new tech-
nology across a large array of scientific fields in a record amount of time. Nanopore
reads are long, often reaching lengths greater than 100 kb,98 and typically captureIDC1037_proof ■ 12 September 2020 ■ 4:45 pm
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507entire genomic fragments, which facilitates downstream analysis of the genomic
context when ARGs are identified.99 This is significant particularly for clinical applica-
tions that aim at reducing TAT, particularly when a culture-independent, direct pro-
cessing method to detect mixed microbial populations in samples is needed. In that
respect, Cao and colleagues100 demonstrated that bacterial species and strain infor-
mation could be obtained within 30 minutes of nanopore sequencing based on
approximately 500 reads, whereas initial drug-resistance profiles could be established
in less than 2 hours, and complete resistance profiles could be available within
10 hours.
Whole-genome sequencing–based AMR predictions and antibiotic-resistance
phenotypes often are concordant, with high sensitivity and specificity (>95%) re-
ported for many phenotypes across several pathogen species,101 although some
notable exceptions were found, such as with levofloxacin resistance in P aeruginosa,
where sensitivity and specificity may be below 95%.102 Successful genomic applica-
tions in the context of bacterial drug-resistance characterization include the analysis
of the structure and insertion site of an antibiotic resistance island in Salmonella
Typhi103 and the characterization of carbapenemase and ESBL genes in gram-neg-
atives.104,105 A functional metagenomics approach combined with nanopore
sequencing was reported by van der Helm and colleagues99 to characterize the
resistome of clinical samples: clones from metagenomic expression libraries,
derived from fecal samples obtained from an ICU patient, which could grow on
each of a panel of 7 antibiotics, were selected, pooled, and barcoded with custom
adapters and sequenced with the MinION nanopore sequencer. Resistome profiling
identified a variety of ARGs with annotation accuracies of greater than 97% mean
sequence identity, such as blaCTX-M and blaTEM, genes coding for aminoglycoside-
modifying enzymes, and diverse genes encoding ribosomal and efflux mediated
resistance to tetracycline antibiotics.
Despite successful applications for strain identification and resistome profiling,
emerging sequencing technologies that offer real-time, long-read, single-molecule
sequencing of DNA or RNA molecules need further development in terms of (1) sensi-
tivity, especially when applied to mixed samples, for which high-sequence yields
providing sufficient genome coverage are required100; (2) sequencing accuracy to
overcome the high error rate of the current nanopore sequencing technology (currently
at approximately 4% per raw read), so that AMR-associated with mutations in chro-
mosomal genes also can be identified104 or multilocus sequencing typing schemes
that attempt to identify bacterial strains from nanopore data be obtained reliably92,100;
meanwhile, several postsequencing algorithms may be used to produce polished
reads with accuracy greater than 98% to 99%; those algorithms include several
rounds of mapping the raw reads to a consensus sequence in order to improve the
overall consensus sequence quality99,106; (3) costs of flow cell and associated con-
sumables107; and (4) easy-to-use bioinformatic tools and interfaces that facilitate
the interpretation of the sequencing results by clinicians and that would enable a
broader adoption of the technology in clinical settings in different countries.108
Overall, single-molecule, real-time sequencing technologies, which may help better
identify and characterize the genomic makeup of drug-resistant bacteria, have been
shown not only to be technically feasible but also time and cost effective. Moreover,
portable technology and rapid TAT provide actionable results with respect to infection
control, implementation of personalized antibiotic treatment in high-risk patients, and
on-site monitoring of resistome in both clinical and environmental settings. It is hoped
that diagnostic laboratories soon will be able to implement routine genome
sequencing as part of their surveillance programs for drug-resistant bacteria.IDC1037_proof ■ 12 September 2020 ■ 4:45 pm
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558DISCUSSION
The spread of extensively drug-resistant and pan–drug-resistant gram-negatives has
challenged the clinical microbiology laboratory to recognize the presence of respon-
sible resistance mechanisms, appreciate their clinical significance, and develop tech-
niques to rapidly detect their existence. This overall challenge is significant and, in
many instances, difficult to address when conventional AST fails to recognize the
presence of clinically important resistance mechanisms, such as ESBLs and carbape-
nemases. A further challenge is to rapidly detect these resistance traits in established
cultures as well as directly from specimens. This review shows the impressive ad-
vances that have been made in rapid detection of resistance in cultures (eg, positive
BCs). Moreover, direct detection of ARGs from screening specimens (eg, rectal
swabs) is a reality, whereas that from other primary samples (eg, whole blood) in
the routine clinical context still is on the horizon.
There also is the inherent conflict between choosing between phenotypic and geno-
typic methods. Genotypic methods are rapid and can be used to test cultures as well
as specimens but are limited by the complexity of the genetic targets and the
continuing emergence of new resistance mechanisms. Phenotypic methods are
slow and best suited for use on cultures, but speed has been improved significantly
using rapid AST systems. It is likely that these challenges will continue as new resis-
tance mechanisms emerge and that phenotypic and genotypic methods will continue
to be needed and used in parallel.
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